Related Experiment Videos
Thrombocytopenia associated with carbamazepine: a case series
M Tohen1, J Castillo, J O Cole
1Department of Psychiatry, Harvard Medical School, Belmont, Mass.
The Journal of Clinical Psychiatry
|December 1, 1991
Summary
Carbamazepine, used for bipolar disorder, can cause thrombocytopenia (low platelets). This serious side effect typically appears within two weeks of starting treatment and resolves quickly after discontinuing the drug.
Area of Science:
- Pharmacology
- Hematology
- Psychiatry
Background:
- Carbamazepine is a widely prescribed medication for bipolar disorder management.
- Thrombocytopenia is a significant adverse effect associated with carbamazepine therapy.
- Understanding the temporal relationship between carbamazepine initiation and thrombocytopenia is crucial for patient safety.
Observation:
- Four cases of bipolar disorder patients experiencing thrombocytopenia during carbamazepine treatment were analyzed.
- Thrombocytopenia onset was consistently observed between 14 to 16 days after carbamazepine initiation.
- Platelet counts normalized within 7 days following the cessation of carbamazepine.
Findings:
- Carbamazepine-induced thrombocytopenia occurs early in the treatment course.
- The condition demonstrates rapid reversibility upon drug discontinuation.
- This suggests a direct, likely immune-mediated, mechanism related to carbamazepine exposure.
Implications:
- Clinicians must be vigilant for early signs of thrombocytopenia in patients taking carbamazepine.
- Prompt recognition and discontinuation of carbamazepine can prevent severe hematologic complications.
- This highlights the importance of monitoring blood counts during carbamazepine therapy for bipolar disorder.